Immunovant (NASDAQ:IMVT) Price Target Raised to $45.00 at Cantor Fitzgerald
Immunovant (NASDAQ:IMVT – Free Report) had its price target hoisted by Cantor Fitzgerald from $30.00 to $45.00 in a report issued on Monday, Benzinga reports. They currently have an overweight rating on the stock. A number of other research analysts have also commented on the stock. UBS Group upgraded shares of Immunovant from a neutral […]
Source: tickerreport.com